Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL'HIV Trial.
Options
BORIS DOI
Date of Publication
November 2024
Publication Type
Article
Division/Institute
Contributor
Marinosci, Annalisa | |
Sculier, Delphine | |
Institute of Social and Preventive Medicine | |
Yerly, Sabine | |
Stoeckle, Marcel | |
Bernasconi, Enos | |
Braun, Dominique L | |
Vernazza, Pietro | |
Cavassini, Matthias | |
Decosterd, Laurent | |
Günthard, Huldrych F | |
Schmid, Patrick | |
Limacher, Andreas | Department of Clinical Research, Clinical Trials Unit Bern |
Calmy, Alexandra |
Subject(s)
Series
Open Forum Infectious Diseases
ISSN or ISBN (if monograph)
2328-8957
Publisher
Oxford University Press
Language
English
Publisher DOI
PubMed ID
39507885
Description
The SIMPL'HIV study investigated whether switching to dolutegravir (DTG) + emtricitabine (FTC) was noninferior to continuing combined antiretroviral therapy for maintaining HIV-1 suppression at 144 weeks. The study demonstrated that viral suppression, CD4 gains, adverse events, quality of life, and patient satisfaction were comparable between groups, confirming DTG + FTC's safety and efficacy for long-term management of HIV-1 infection.
File(s)
| File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
|---|---|---|---|---|---|---|---|
| ofae618.pdf | text | Adobe PDF | 453.76 KB | published |